A review of contact activation system studies indicates that Factor XIa inhibition may reduce the risk of secondary noncardioembolic stroke without significantly increasing major bleeding. In OCEANIC-STROKE, the rates of clinical recurrent ischemic stroke were 6.2 percent in the asundexian 50-milligram daily group and 8.4 percent in the placebo group, with a cause-specific risk ratio of 0.74.
Source:BIOENGINEER.ORG · Read Original
Leave a Reply